| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 90 | 90 | 6 |
| Full Text Views | 250 | 65 | 0 |
| PDF Downloads | 63 | 22 | 0 |
No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine.
Artemether-lumefantrine is a new fixed antimalarial combination effective against multidrug-resistant falciparum malaria. A prospective electrocardiographic study was conducted in 150 patients receiving artemetherlumefantrine and 50 treated with artesunate-mefloquine. There was no evidence for clinically significant changes in the electrocardiographic intervals and in particular no relationship between plasma concentrations of lumefantrine and QTc prolongation. Artemether-lumefantrine does not have significant cardiac effects at therapeutic doses.